CoChat
Sign Up
Cited by 16

The DOI matches its Crossref record.

miR-128 enhances dendritic cell-mediated anti-tumor immunity via targeting of p38

Liang, Xue, Shangguan, Wenfeng, Zhang, Miaomiao, Mei, Shiyue, Wang, Liyang, Yang, Rongcun·2017·Molecular Medicine Reports
DOI 10.3892/mmr.2017.6717PMC PMC5561786
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/mmr.2017.6717

Cites

Statistics

Figures

Figure 1. Expression of miR-128 and p38 levels in DCs as a response to B16 stimulation. (A) miR-128, (B) p38 mRNA and (C) p38 protein expression levels in DCs following B16 stimulation. Difference between two groups was analyzed by t-test. *P<0.05 vs. control. miR, miRNA; DC, dendritic cells.
Figure 1. Expression of miR-128 and p38 levels in DCs as a response to B16 stimulation. (A) miR-128, (B) p38 mRNA and (C) p38 protein expression levels in DCs following B16 stimulation. Difference between two groups was analyzed by t-test. *P<0.05 vs. control. miR, miRNA; DC, dendritic cells.CC BY-NC-ND · PubMed Central
Figure 2. Effect of miR-128 on p38 expression levels in DCs. (A) Expression of p38 gene was not significantly altered by miR-128 mimic or inhibitor in DCs. (B) Effects of differing doses of miR-128 mimic (1, 10 or 100 nM) on p38 gene expression. (C) Effects of differing doses of miR-128 inhibitor (1, 10 or 100 nM) on p38 gene expression. (D) miR-128 mimic and inhibitor had markedly contrasting effects in the regulation of the expression of p38 protein. (E) Effects of differing doses of miR-128 mimic (1, 10 or 100 nM) on p38 protein. miR-128 mimic demonstrated a dose-dependent effect on the inhibition of p38 protein. (F) Effects of differing doses of miR-128 inhibitor (1, 10 or 100 nM) on p38 protein. p38 protein accumulation was enhanced by miR-128 inhibitor in a dose-dependent manner. Differences among groups were analyzed by one-way analysis of variance. NC, negative control dsRNA that did not target any gene; miR, miRNA; DC, dendritic cells.
Figure 2. Effect of miR-128 on p38 expression levels in DCs. (A) Expression of p38 gene was not significantly altered by miR-128 mimic or inhibitor in DCs. (B) Effects of differing doses of miR-128 mimic (1, 10 or 100 nM) on p38 gene expression. (C) Effects of differing doses of miR-128 inhibitor (1, 10 or 100 nM) on p38 gene expression. (D) miR-128 mimic and inhibitor had markedly contrasting effects in the regulation of the expression of p38 protein. (E) Effects of differing doses of miR-128 mimic (1, 10 or 100 nM) on p38 protein. miR-128 mimic demonstrated a dose-dependent effect on the inhibition of p38 protein. (F) Effects of differing doses of miR-128 inhibitor (1, 10 or 100 nM) on p38 protein. p38 protein accumulation was enhanced by miR-128 inhibitor in a dose-dependent manner. Differences among groups were analyzed by one-way analysis of variance. NC, negative control dsRNA that did not target any gene; miR, miRNA; DC, dendritic cells.CC BY-NC-ND · PubMed Central
Figure 3. Effects of miR-128 and p38 on the mRNA and secretion levels of cytokines IL-6, −10 and −12 in DCs. The immature DCs were transfected with miR-128 mimic or inhibitor, or p38 inhibitor. Following this, cells were treated with lipopolysaccharide to promote the maturation of DCs. The mRNA expression of genes encoding (A) IL-6, (B) IL-10 and (C) IL-12 were detected via reverse transcription-quantitative polymerase chain reaction and the secretion levels were determined by ELISA during the 24 h treated time course. Differences among groups were analyzed by one-way analysis of variance, followed by Bonferroni's multiple comparison test. *P<0.05 vs. control; #P<0.05 vs. miR-128 mimic group. NC, negative control dsRNA that did not target any gene; miR, miRNA; DC, dendritic cells; IL, interleukin.
Figure 3. Effects of miR-128 and p38 on the mRNA and secretion levels of cytokines IL-6, −10 and −12 in DCs. The immature DCs were transfected with miR-128 mimic or inhibitor, or p38 inhibitor. Following this, cells were treated with lipopolysaccharide to promote the maturation of DCs. The mRNA expression of genes encoding (A) IL-6, (B) IL-10 and (C) IL-12 were detected via reverse transcription-quantitative polymerase chain reaction and the secretion levels were determined by ELISA during the 24 h treated time course. Differences among groups were analyzed by one-way analysis of variance, followed by Bonferroni's multiple comparison test. *P<0.05 vs. control; #P<0.05 vs. miR-128 mimic group. NC, negative control dsRNA that did not target any gene; miR, miRNA; DC, dendritic cells; IL, interleukin.CC BY-NC-ND · PubMed Central
Figure 4. Role of miR-128 and p38 in the therapeutic effect of DCs. (A) Final tumor volume, (B) tumor growth plot, (C) animal survival time and (D) final tumor weight were assessed in C57BL/6 mice bearing B16 melanoma following injection with DCs harboring negative control oligonucleotide, miR-128 mimic or inhibitor, or p38 inhibitor. Differences among groups were analyzed by one-way analysis of variance, followed by Bonferroni's multiple comparison test. *P<0.05 vs. control; #P<0.05 vs. miR-128 mimic group. NC, negative control dsRNA that did not target any gene; miR, miRNA; DC, dendritic cells.
Figure 4. Role of miR-128 and p38 in the therapeutic effect of DCs. (A) Final tumor volume, (B) tumor growth plot, (C) animal survival time and (D) final tumor weight were assessed in C57BL/6 mice bearing B16 melanoma following injection with DCs harboring negative control oligonucleotide, miR-128 mimic or inhibitor, or p38 inhibitor. Differences among groups were analyzed by one-way analysis of variance, followed by Bonferroni's multiple comparison test. *P<0.05 vs. control; #P<0.05 vs. miR-128 mimic group. NC, negative control dsRNA that did not target any gene; miR, miRNA; DC, dendritic cells.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 36

  1. Ferlay, 2015, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210 · DOI · Paper page
  2. Guo, 2015, Chinese guidelines on the diagnosis and treatment of melanoma (2015 Edition), Ann Transl Med, 3, 322
  3. Henderson, 2013, Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.1. 02/TROG 02.01), J Clin Oncol, 31, S9001, 10.1200/jco.2013.31.15_suppl.9001 · DOI
  4. Walker, 2005, Phase II trial of weekly paclitaxel in patients with advanced melanoma, Melanoma Res, 15, 453, 10.1097/00008390-200510000-00015 · DOI
  5. Avril, 2004, Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study, J Clin Oncol, 22, 1118, 10.1200/JCO.2004.04.165 · DOI
  6. Steinman, 2012, Decisions about dendritic cells: Past, present, and future, Annu Rev Immunol, 30, 1, 10.1146/annurev-immunol-100311-102839 · DOI
  7. Banchereau, 1998, Dendritic cells and the control of immunity, Nature, 392, 245, 10.1038/32588 · DOI
  8. Palucka, 2012, Cancer immunotherapy via dendritic cells, Nat Rev Cancer, 12, 265, 10.1038/nrc3258 · DOI
  9. Mackensen, 2000, Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells, Int J Cancer, 86, 385, 10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T · DOI
  10. Nestle, 1998, Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells, Nat Med, 4, 328, 10.1038/nm0398-328 · DOI · Paper page
  11. Oshita, 2012, Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial, Oncol Rep, 28, 1131, 10.3892/or.2012.1956 · DOI
  12. Engell-Noerregaard, 2009, Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: Assessment of correlation between clinical response and vaccine parameters, Cancer Immunol Immunother, 58, 1, 10.1007/s00262-008-0568-4 · DOI
  13. Bol, 2016, Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination, Oncoimmunology, 5, e1057673, 10.1080/2162402X.2015.1057673 · DOI
  14. Gabrilovich, 2004, Mechanisms and functional significance of tumour-induced dendritic-cell defects, Nat Rev Immunol, 4, 941, 10.1038/nri1498 · DOI
  15. Xie, 2005, Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells, Exp Hematol, 33, 564, 10.1016/j.exphem.2005.03.001 · DOI
  16. Wang, 2006, Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells, Blood, 108, 4071, 10.1182/blood-2006-04-016980 · DOI
  17. Lawson, 2013, p38α mitogen-activated protein kinase depletion and repression of signal transduction to translation machinery by miR-124 and −128 in neurons, Mol Cell Biol, 33, 127, 10.1128/MCB.00695-12 · DOI
  18. Shi, 2012, MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1, PLoS One, 7, e32709, 10.1371/journal.pone.0032709 · DOI
  19. Hu, 2014, microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C, Eur J Cancer, 50, 2336, 10.1016/j.ejca.2014.06.005 · DOI
  20. Li, 2013, miR-128 and its target genes in tumorigenesis and metastasis, Exp Cell Res, 319, 3059, 10.1016/j.yexcr.2013.07.031 · DOI
  21. Zhang, 2010, Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3, Cancer Res, 70, 89, 10.1158/0008-5472.CAN-09-2970 · DOI
  22. Min, 2013, Multiple tumor-associated microRNAs modulate the survival and longevity of dendritic cells by targeting YWHAZ and Bcl2 signaling pathways, J Immunol, 190, 2437, 10.4049/jimmunol.1202282 · DOI
  23. Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method, Methods, 25, 402, 10.1006/meth.2001.1262 · DOI · Paper page
  24. Anderson, 2008, Post-transcriptional control of cytokine production, Nat Immunol, 9, 353, 10.1038/ni1584 · DOI · Paper page
  25. Cargnello, 2011, Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases, Microbiol Mol Biol Rev, 75, 50, 10.1128/MMBR.00031-10 · DOI · Paper page
  26. Godlewski, 2008, Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal, Cancer Res, 68, 9125, 10.1158/0008-5472.CAN-08-2629 · DOI · Paper page
  27. Guerau-de-Arellano, 2011, Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity, Brain, 134, 3578, 10.1093/brain/awr262 · DOI · Paper page
  28. Chomarat, 2000, IL-6 switches the differentiation of monocytes from dendritic cells to macrophages, Nat Immunol, 1, 510, 10.1038/82763 · DOI
  29. Park, 2004, IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation, J Immunol, 173, 3844, 10.4049/jimmunol.173.6.3844 · DOI · Paper page
  30. McBride, 2002, IL-10 alters DC function via modulation of cell surface molecules resulting in impaired T-cell responses, Cell Immunol, 215, 162, 10.1016/S0008-8749(02)00007-2 · DOI
  31. Fortsch, 2000, IL-10 converts human dendritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis, J Immunol, 165, 978, 10.4049/jimmunol.165.2.978 · DOI
  32. Corinti, 2001, Regulatory activity of autocrine IL-10 on dendritic cell functions, J Immunol, 166, 4312, 10.4049/jimmunol.166.7.4312 · DOI
  33. Trombetta, 2005, Cell biology of antigen processing in vitro and in vivo, Annu Rev Immunol, 23, 975, 10.1146/annurev.immunol.22.012703.104538 · DOI
  34. Clatworthy, 2014, Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes, Nat Med, 20, 1458, 10.1038/nm.3709 · DOI
  35. Sharma, 1999, T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function, J Immunol, 163, 5020, 10.4049/jimmunol.163.9.5020 · DOI
  36. Jarnicki, 2008, Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics, J Immunol, 180, 3797, 10.4049/jimmunol.180.6.3797 · DOI

Cited by

Sorted by citations

Metadata

Authors
Liang, X., Shangguan, W., Zhang, M., Mei, S., Wang, L., & Yang, R.
Venue
Molecular Medicine Reports
Publisher
Spandidos Publications
Published
2017-02
Volume
16
Issue
2
Pages
1307-1313
ISSN
  • 1791-2997
  • 1791-3004
DOI
10.3892/mmr.2017.6717
PMC
PMC5561786
Cited by
16
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review